Monitor the company's ATM sales disclosures in future filings to gauge the pace and size of actual share issuance. The $25 million authorization represents a significant potential overhang for a clinical-stage biotech with no disclosed revenue.
Price Chart
Executive Summary
CalciMedica filed a prospectus supplement to sell up to $25 million of common stock under an existing at-the-market offering agreement with H.C. Wainwright & Co., utilizing its effective shelf registration statement. This is a routine capital-raising update that increases potential dilution for existing shareholders.
Key Facts
- CalciMedica may offer and sell up to $25,000,000 of common stock under an ATM agreement with H.C. Wainwright & Co.
- The prospectus supplement was filed on September 30, 2026, under the company's existing shelf registration (Form S-3, No. 333-293972).
- The shelf registration was initially filed on March 3, 2026, and declared effective on March 11, 2026.
- The legal opinion from Cooley LLP confirms the shares will be validly issued, fully paid, and nonassessable when sold.
Financial Impact
Up to $25,000,000 in potential common stock sales, causing dilution for existing shareholders.
Risk Factors
- Dilution from future share sales under the ATM program.
- Potential downward pressure on stock price as shares are sold into the market.
- No disclosed revenue or profitability — reliance on equity financing for operations.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409049 |
| Document: d39303dex51.htm | 0001193125-26-409049 |
| Document: 0001193125-26-409049-index-headers.html | 0001193125-26-409049 |
| Document: 0001193125-26-409049-index.html | 0001193125-26-409049 |
| Document: 0001193125-26-409049.txt | 0001193125-26-409049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.02 | awaiting T+20 | — | $1.32 (−29.41%) |
Sep 30, 2026 26d ago | 8-K | $1.65 | awaiting T+20 | — | $1.32 (+20.00%) |
Sep 30, 2026 26d ago | 424B5 | $1.65 | awaiting T+20 | — | $1.32 (+20.00%) |
Sep 2, 2026 7w ago | 8-K | $2.10 $1.65 | ▲ +21.43% | ▲ +21.28% | $1.32 (+37.14%) |
Aug 11, 2026 11w ago | 8-K | $0.6577 $0.4590 | ▲ +30.21% | ▲ +29.15% | $1.32 (−100.70%) |
Aug 11, 2026 11w ago | Press Release | $0.6577 $0.4590 | ▼ −30.21% | ▼ −29.15% | $1.32 (+100.70%) |
Jul 10, 2026 15w ago | 3 | $0.8178 $0.6590 | ▼ −19.42% | ▼ −22.60% | $1.32 (+61.41%) |
Jun 24, 2026 17w ago | 8-K | $0.5973 $0.7159 | ▼ −19.86% | ▼ −19.18% | $1.32 (−120.99%) |
May 12, 2026 24w ago | 8-K | $0.6300 $0.9320 | ▲ +47.94% | ▲ +49.66% | $1.32 (+109.52%) |
Mar 12, 2026 32w ago | EFFECT | $0.7260 $0.6180 | ▼ −14.88% | ▼ −16.85% | $1.32 (+81.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers